Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies. Uncovering the exposure relationships that provide selective adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperling, Adam S., Guerra, Veronica A., Kennedy, James A., Yan, Yuanqing, Hsu, Joanne I., Wang, Feng, Nguyen, Andrew T., Miller, Peter G., McConkey, Marie E., Quevedo Barrios, Vanessa A., Furudate, Ken, Zhang, Linda, Kanagal-Shamanna, Rashmi, Zhang, Jianhua, Little, Latasha, Gumbs, Curtis, Daver, Naval, DiNardo, Courtney D., Kadia, Tapan, Ravandi, Farhad, Kantarjian, Hagop, Garcia-Manero, Guillermo, Futreal, P. Andrew, Ebert, Benjamin L., Takahashi, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Plenary Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837415/
https://www.ncbi.nlm.nih.gov/pubmed/35512188
http://dx.doi.org/10.1182/blood.2021014956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837415/
https://www.ncbi.nlm.nih.gov/pubmed/35512188
http://dx.doi.org/10.1182/blood.2021014956

Ejemplares similares